Aims: To examine objective visual acuity measured with ETDRS, retinal thickness (OCT), and patient reported outcome measurements in patients treated with anti-VEGF treatment for visual impairment due to DME in routine clinical care after 12 months.
Methods: In this cross-sectional study, 58 patients (29 females and 29 males; mean age, 68 years) with type 1 and type 2 diabetes diagnosed with macular edema were included. Medical data and two questionnaires were collected; an eye-specific (NEI VFQ-25) and a generic health-related quality of life questionnaire (SF-36) were used after anti-VEGF treatment.
Results: Thirty patients had significantly improved visual acuity (p-value ˂ 0.001), and 27 patients had no improved visual acuity at 12 months. Both groups had significantly (p-value ˂ 0.001), reduced retinal thickness (OCT). The patients with improved visual acuity had significantly improved scores for NEI VFQ-25 subscales including general health (p-value ˂ 0.004),, general vision (p-value - 0.001), near activities (p-value- 0.015), distance activities (p-value- 0.008), and composite score (p-value 0.024), but no significant changes in scores were found in the group without improvements in visual acuity.
Conclusions: The patient-reported outcome measurements improved in the total patient population. A high HbA1c at baseline may be a risk factor for poor treatment effects.
patient-reported measurements, diabetic macular edema, anti-VEGF treatment, visual function